8th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting - KIDNEY CANCER

Friday, November 13, 2026

12:50 - 14:30 CET

Moderator(s)

At the end of this session, attendees should be able to:

Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
Recognize the role of imaging and genetic markers in guiding treatment decision-making.
Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

12:50 - 13:05 CET

KIM-1 as a Prognostic Biomarker in RCC
Speaker: Wenxin (Vincent) Xu – Dana-Farber Cancer Institute
13:05 CET

Debate: Open vs Robotic Surgery in IVC Thrombus
Moderator: Simon Tanguay – McGill University
13:05 - 13:13 CET

Open
Speaker: Philippe E. Spiess – Moffitt Cancer Center
13:13 - 13:21 CET

Robotic
Speaker: Jean-Christophe Bernhard – CHU Bordeaux - I.CaRe Bordeaux
13:21 - 13:30 CET

Discussion and Q&A
Moderator: Simon Tanguay – McGill University
Speaker: Philippe E. Spiess – Moffitt Cancer Center
Speaker: Jean-Christophe Bernhard – CHU Bordeaux - I.CaRe Bordeaux
13:30 - 13:45 CET

Adjuvant Treatment for Localized RCC
13:45 - 14:15 CET

Case-Based Discussion: What Is the Best Approach for Robotic Partial Nephrectomy?
Moderator: Simon Tanguay – McGill University
13:45 - 14:15 CET

Retro
Speaker: Alexis Rompré-Brodeur
13:45 - 14:15 CET

Trans
Speaker: Umberto Capitanio – Vita-Salute San Raffaele
14:15 - 14:30 CET

Metastatic RCC - Second-Line Treatment and Beyond